organophosphonates has been researched along with Sexually Transmitted Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hogben, M; Liddon, N | 1 |
| Mwethera, PG; Obiero, J; Wiysonge, CS | 1 |
| Thompson, M | 1 |
| Balán, IC; Carballo-Diéguez, A; El-Sadr, W; Gai, F; Hoffman, S; Mantell, JE; Maslankowski, L; Mayer, K; Morrow, K; Rosen, R | 1 |
1 review(s) available for organophosphonates and Sexually Transmitted Diseases
| Article | Year |
|---|---|
Topical microbicides for prevention of sexually transmitted infections.
Topics: Acrylic Resins; Adenine; Administration, Topical; Agaricales; Anti-HIV Agents; Anti-Infective Agents, Local; Cellulose; Female; HIV Infections; Humans; Male; Naphthalenesulfonates; Organophosphonates; Polymers; Seaweed; Sexually Transmitted Diseases; Tenofovir | 2012 |
1 trial(s) available for organophosphonates and Sexually Transmitted Diseases
| Article | Year |
|---|---|
Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Patient Satisfaction; Sexually Transmitted Diseases; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2007 |
2 other study(ies) available for organophosphonates and Sexually Transmitted Diseases
| Article | Year |
|---|---|
Disinhibition and risk compensation: scope, definitions, and perspective.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Counseling; Female; HIV Infections; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Reduction Behavior; Safe Sex; Sex Work; Sexual Behavior; Sexually Transmitted Diseases; Tenofovir | 2008 |
The experts speak. Studying the potential of tenofovir to prevent sexual transmission of HIV: first steps. Interview by Vicki Glaser.
Topics: Adenine; Communicable Disease Control; Female; HIV Infections; Humans; Male; Organophosphonates; Primary Prevention; Risk Assessment; Sensitivity and Specificity; Sexually Transmitted Diseases; Tenofovir; Treatment Outcome | 2005 |